Samsung Biologics selects Rapid Micro Biosystems’ Growth Direct® platform to automate critical microbiology quality control testing

LOWELL, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that Samsung Biologics (KRX: 207940.KS) has selected the Growth Direct® platform to automate its microbial quality control processes to deliver increased efficiency, more robust data integrity and scalable quality control operations.

“Samsung Biologics is a leading global contract development and manufacturing organization (CDMO) and has demonstrated an unwavering commitment to automation and quality management in biopharmaceutical manufacturing,” said Robert Spignesi, President and CEO of Rapid Micro Biosystems. “The Growth Direct® improves operational efficiency and data integrity in the quality control microbiology lab, and we are proud to partner with Samsung Biologics.”

Global pharmaceutical manufacturers rely on the Growth Direct platform to meet both today’s microbiological quality control standards and tomorrow’s challenges. It is the only fully automated, non-destructive growth-based platform for microbiology quality control testing that offers faster time to results, improved data integrity, and enhanced accuracy, with greater sample capacity.

To learn more about the Company and the Growth Direct® platform please visit: Rapid Micro Biosystems.

About Rapid Micro Biosystems 

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Lexington, Massachusetts, Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on Twitter at @rapidmicrobio or on LinkedIn.

About Samsung Biologics Co., Ltd.

Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing support for the biopharmaceutical products we manufacture. Our state-of-the-art facilities are cGMP compliant with bioreactors ranging from small to large scales to serve varying client needs. To maximize our operational efficiency and expand our capabilities in response to growing biomanufacturing demand, Samsung Biologics recently completed Bio Campus I with Plant 4 offering a combined 604KL total capacity, and launched Bio Campus II with the construction of Plant 5, which will be operational in April 2025 adding 184KL biomanufacturing capacity. Additionally, Samsung Biologics America enables the company to work in closer proximity to clients based in the U.S. and Europe. We continue to upgrade our capabilities to accommodate our clients by investing in technologies such as an antibody-drug conjugate (ADC) facility, a dedicated mRNA manufacturing facility, and additional aseptic filling capacity. As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the expected impact of the Growth Direct system on Samsung Biologics' operational efficiency and data integrity.

Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the important factors outlined under the caption “Risk Factors” in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 10, 2023, as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.


Rapid Micro Biosystems Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications investors@rapidmicrobio.com Rapid Micro Biosystems Media Contact: media@rapidmicrobio.com Samsung Biologics Media Contact Claire Kim, Head of Marketing Communications cair.kim@samsung.com


Samsung Biologics selects Rapid Micro Biosystems’ Growth Direct® platform to automate critical microbiology quality control testing

THỦ THUẬT HAY

Cách tắt lời nhắc thông báo trên Bixby Galxy S8

Bixby là trợ lý ảo lần đầu tiên xuất hiện trên Galaxy S8, được tích hợp sẵn tên thiết bị.

Hướng dẫn hạ cấp về lại iOS 10

Phiên bản duy nhất mà chúng ta có thể hạ là 10.3.3 vì những bản thấp hơn đã bị khoá sign rồi. Việc hạ cấp đơn giản nên chúng tạ tự thực hiện cũng được, quan trọng là chọn đúng bản firmware cho thiết bị nếu không sẽ xảy

Cài đặt Windows Timeline Support trên trình duyệt Chrome, Firefox và Vivaldi

Về cơn bản, Windows Timeline là tính năng hỗ trợ, nó tạo ra các snapshot của ứng dụng, web hay bất cứ chương trình nào mà người dùng đã sử dụng và khôi phục trong thời gian 30 ngày.

Ngoài mở khoá màn hình, phím Home trên iPhone còn có thể làm gì?

Nút Home tròn có thể xem là một đặc trưng của dòng sản phẩm iPhone, iPad đến từ Apple. Không chỉ cho phép người dùng quay lại màn hình chủ, truy cập đa nhiệm, mà nó còn có khả năng kích hoạt nhanh các tính năng mà có

Hướng dẫn cách vô hiệu hóa Messenger trên điện thoại đơn giản, nhanh chóng

Trong một khoảng thời gian dài sử dụng, bạn muốn tạm thời vô hiệu hóa Messenger trên điện thoại để có thể tập trung hơn trong việc học cũng như trong công việc, nhưng không phải ai cũng biết đến cách làm này.

ĐÁNH GIÁ NHANH

Đánh giá OPPO F7: Đáng lựa chọn trong phân khúc tầm trung

Dẫu không đi theo xu hướng camera sau kép, OPPO F7 vẫn đáp ứng khá tốt cho nhu cầu chụp ảnh thực tế đối với người dùng phổ thông. Máy cũng đi theo trào lưu thiết kế màn hình 'tai thỏ' nhằm tối ưu không gian màn hình,

Trên tay Realme Pad: Đây là máy tính bảng giá rẻ sao?

Giá rẻ đồng nghĩa với cấu hình thấp, thiết kế không nổi bật,… Nhưng khi trên tay Realme Pad thì hoàn toàn khác. Một chiếc tablet thế hệ mới không chỉ có giá siêu mềm mà còn sở hữu thiết kế sang trọng, hiện đại và phần